Home > Insider Trading > Filing (0001493152-24-020660)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1610820	Briacell Therapeutics Corp.	BCTX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1940908	Marc Lustig	C/O Briacell Therapeutics Corp. 235 15Th Street,Suite 300 West Vancouver A1 V7T 2X1		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2024-05-14	902,935	$2.22	2,542,935	No	4	P	Indirect	By L5 Capital Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By L5 Capital Inc.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrants	Acquisiton	2024-05-14	902,935	$0.00	902,935	$2.11

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
902,935			No	4	P	Indirect

Footnotes

The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.